GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embla Medical hf (OCSE:EMBLA) » Definitions » EV-to-EBIT

Embla Medical hf (OCSE:EMBLA) EV-to-EBIT : 24.48 (As of May. 12, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Embla Medical hf EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Embla Medical hf's Enterprise Value is kr15,728 Mil. Embla Medical hf's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr642 Mil. Therefore, Embla Medical hf's EV-to-EBIT for today is 24.48.

The historical rank and industry rank for Embla Medical hf's EV-to-EBIT or its related term are showing as below:

OCSE:EMBLA' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.65   Med: 26.6   Max: 162.98
Current: 24.48

During the past 13 years, the highest EV-to-EBIT of Embla Medical hf was 162.98. The lowest was 12.65. And the median was 26.60.

OCSE:EMBLA's EV-to-EBIT is ranked worse than
57.36% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 20.82 vs OCSE:EMBLA: 24.48

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Embla Medical hf's Enterprise Value for the quarter that ended in Mar. 2024 was kr17,631 Mil. Embla Medical hf's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr642 Mil. Embla Medical hf's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 3.64%.


Embla Medical hf EV-to-EBIT Historical Data

The historical data trend for Embla Medical hf's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embla Medical hf EV-to-EBIT Chart

Embla Medical hf Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.40 167.02 31.96 35.80 22.20

Embla Medical hf Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.03 30.83 24.64 22.20 27.45

Competitive Comparison of Embla Medical hf's EV-to-EBIT

For the Medical Devices subindustry, Embla Medical hf's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embla Medical hf's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Embla Medical hf's EV-to-EBIT falls into.



Embla Medical hf EV-to-EBIT Calculation

Embla Medical hf's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=15728.380/642.39
=24.48

Embla Medical hf's current Enterprise Value is kr15,728 Mil.
Embla Medical hf's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr642 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embla Medical hf  (OCSE:EMBLA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Embla Medical hf's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=642.39/17630.52
=3.64 %

Embla Medical hf's Enterprise Value for the quarter that ended in Mar. 2024 was kr17,631 Mil.
Embla Medical hf's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr642 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embla Medical hf EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Embla Medical hf's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Embla Medical hf (OCSE:EMBLA) Business Description

Traded in Other Exchanges
Address
Grjothals 5, Reykjavik, ISL
Ossur hf is engaged in the design, development, manufacture, and sale of prosthetics and bracing & support products. The company's products improve mobility through technologies in the field of braces, supports, prosthetic limbs, and compression therapy. Its segments are the Bracing & Supports and Prosthetics segment. The bracing & support products are used to support joints and other body parts for therapeutic and preventative purposes. The Prosthetics segment includes artificial limbs and related products for individuals born without limbs. Its geographical segments are the Americas; Europe, the Middle East & Africa (EMEA); and the Americas & Asia-Pacific (APAC), of which the Americas generate nearly half of the company's revenue.

Embla Medical hf (OCSE:EMBLA) Headlines

No Headlines